Insider Transactions in Q1 2021 at G1 Therapeutics, Inc. (GTHX)
Insider Transaction List (Q1 2021)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 23
2021
|
Rajesh Malik Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
15,000
-25.73%
|
$315,000
$21.94 P/Share
|
|
Mar 23
2021
|
Rajesh Malik Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+20.46%
|
$0
$0.39 P/Share
|
|
Mar 03
2021
|
Jennifer K. Moses CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
3,000
+10.71%
|
$9,000
$3.72 P/Share
|
|
Mar 02
2021
|
Rajesh Malik Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
15,000
-25.73%
|
$330,000
$22.95 P/Share
|
|
Mar 02
2021
|
Rajesh Malik Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+11.77%
|
$30,000
$2.28 P/Share
|
|
Feb 18
2021
|
Mark A. Velleca |
SELL
Open market or private sale
|
Direct |
10,000
-19.61%
|
$260,000
$26.02 P/Share
|
|
Feb 18
2021
|
Mark A. Velleca |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+16.39%
|
$30,000
$3.72 P/Share
|
|
Feb 17
2021
|
Mark A. Velleca |
SELL
Open market or private sale
|
Direct |
10,000
-9.94%
|
$280,000
$28.0 P/Share
|
|
Feb 17
2021
|
Mark A. Velleca |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+16.39%
|
$30,000
$3.72 P/Share
|
|
Feb 16
2021
|
Mark A. Velleca |
SELL
Open market or private sale
|
Direct |
11,040
-7.4%
|
$397,440
$36.03 P/Share
|
|
Feb 16
2021
|
Mark A. Velleca |
BUY
Exercise of conversion of derivative security
|
Direct |
11,040
+17.5%
|
$33,120
$3.72 P/Share
|
|
Jan 27
2021
|
Rajesh Malik Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,100
+6.68%
|
$0
$0.39 P/Share
|
|
Jan 22
2021
|
Rajesh Malik Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
15,000
-27.17%
|
$300,000
$20.64 P/Share
|
|
Jan 22
2021
|
Rajesh Malik Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+21.37%
|
$60,000
$4.17 P/Share
|
|
Jan 21
2021
|
Mark A. Velleca |
SELL
Open market or private sale
|
Direct |
10,000
-19.61%
|
$200,000
$20.64 P/Share
|
|
Jan 21
2021
|
Mark A. Velleca |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+16.39%
|
$30,000
$3.72 P/Share
|
|
Jan 20
2021
|
Mark A. Velleca |
BUY
Exercise of conversion of derivative security
|
Direct |
14,000
+13.22%
|
$28,000
$2.06 P/Share
|
|
Jan 20
2021
|
Mark A. Velleca |
SELL
Open market or private sale
|
Direct |
10,000
-21.28%
|
$210,000
$21.51 P/Share
|
|
Jan 19
2021
|
Mark A. Velleca |
SELL
Open market or private sale
|
Direct |
10,000
-21.28%
|
$200,000
$20.88 P/Share
|
|
Jan 19
2021
|
Mark A. Velleca |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+17.54%
|
$30,000
$3.72 P/Share
|
|
Jan 04
2021
|
Mark Avagliano Chief Business Officer |
BUY
Grant, award, or other acquisition
|
Direct |
11,000
+50.0%
|
-
|
|
Jan 04
2021
|
Terry L Murdock Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
11,000
+50.0%
|
-
|
|
Jan 04
2021
|
Rajesh Malik Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
11,000
+21.48%
|
-
|
|
Jan 04
2021
|
James S. Hanson General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
11,000
+42.31%
|
-
|
|
Jan 04
2021
|
Soma Gupta Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
11,000
+50.0%
|
-
|
|
Jan 04
2021
|
Jennifer K. Moses CFO |
BUY
Grant, award, or other acquisition
|
Direct |
11,000
+33.33%
|
-
|
|
Jan 01
2021
|
John E. (Jack) Bailey Jr. President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
213,333
+49.08%
|
-
|